International Perspectives on the Cost-Effectiveness of Tandem Mass Spectrometry for Rare Metabolic Conditions
dc.contributor.author | Norman, Richard | |
dc.contributor.author | Haas, M. | |
dc.contributor.author | Wilcken, B. | |
dc.date.accessioned | 2017-01-30T11:54:11Z | |
dc.date.available | 2017-01-30T11:54:11Z | |
dc.date.created | 2015-07-16T06:21:52Z | |
dc.date.issued | 2009 | |
dc.identifier.citation | Norman, R. and Haas, M. and Wilcken, B. 2009. International Perspectives on the Cost-Effectiveness of Tandem Mass Spectrometry for Rare Metabolic Conditions. Health Policy. 89: pp. 252-260. | |
dc.identifier.uri | http://hdl.handle.net/20.500.11937/16150 | |
dc.identifier.doi | 10.1016/j.healthpol.2008.08.003 | |
dc.description.abstract |
Objectives: To examine and evaluate the economic evidence regarding the use of tandem mass spectrometry (MS/MS) for the detection of rare metabolic conditions in neonates, and then to consider the transferability of these national-level results to other decision-making contexts.Methods: A systematic literature review was undertaken, identifying papers published between January 1997 and March 2008. Thirteen unique cost-effectiveness evaluations were identified and appraised forcomparability and transferability of results across settings.Results: The primary outcome measure was usually life years gained (LYG) or quality adjusted lifeyears gained (QALY). The incremental cost-effectiveness ratios (ICER) presented were generally supportive of MS/MS, but showed considerable variation. Differences in assumptions made regarding prevalence and prognosis played a significant role in this variation.Conclusions: Differences in study structure, the approach to costing, the choice of intervention, control and outcome measure, and the limit of studies to developed countries makes international generalisation of the cost-effectiveness evidence difficult. The importance of assumptions regarding disease progression and subsequent health care utilisation suggests that further work needs to consider the importance of longer-term follow-up. | |
dc.publisher | Elsevier Ireland Ltd | |
dc.subject | Health economics | |
dc.subject | Cost-effectiveness | |
dc.subject | Review | |
dc.subject | Tandem mass spectrometry | |
dc.subject | Metabolism | |
dc.title | International Perspectives on the Cost-Effectiveness of Tandem Mass Spectrometry for Rare Metabolic Conditions | |
dc.type | Journal Article | |
dcterms.source.volume | 89 | |
dcterms.source.startPage | 252 | |
dcterms.source.endPage | 260 | |
dcterms.source.issn | 0168-8510 | |
dcterms.source.title | Health Policy | |
curtin.accessStatus | Fulltext not available |